{"id":"csl-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site soreness or erythema"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated influenza virus antigens (typically from three or four circulating strains) that trigger both humoral and cell-mediated immune responses. Upon vaccination, B cells produce strain-specific antibodies that neutralize viral particles, while T cells develop memory responses to provide broader protection. This priming of the adaptive immune system reduces infection risk and severity if exposure to wild-type influenza occurs.","oneSentence":"This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:29.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT00964951","phase":"PHASE2","title":"CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza","enrollment":""},{"nctId":"NCT01591837","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2012-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT00825162","phase":"PHASE4","title":"Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-03","conditions":"Influenza","enrollment":1992},{"nctId":"NCT00735475","phase":"PHASE4","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":1268},{"nctId":"NCT00562484","phase":"PHASE4","title":"A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-03","conditions":"Influenza","enrollment":7500},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT02214225","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-08","conditions":"Influenza, Human","enrollment":3484},{"nctId":"NCT00320346","phase":"PHASE2","title":"Phase II Study of Pandemic Influenza Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2006-07","conditions":"Influenza","enrollment":400},{"nctId":"NCT00700193","phase":"PHASE3","title":"A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2005-03","conditions":"Influenza","enrollment":298},{"nctId":"NCT02212106","phase":"PHASE4","title":"A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-09","conditions":"Influenza, Human","enrollment":402},{"nctId":"NCT01412281","phase":"PHASE3","title":"Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-10","conditions":"Influenza","enrollment":440},{"nctId":"NCT01229371","phase":"PHASE3","title":"Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-10","conditions":"Influenza","enrollment":440},{"nctId":"NCT00943488","phase":"PHASE2","title":"CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"Influenza","enrollment":408},{"nctId":"NCT00333398","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"Influenza","enrollment":1359}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":226,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enzira® vaccine","Afluria® vaccine"],"phase":"marketed","status":"active","brandName":"CSL Influenza Vaccine","genericName":"CSL Influenza Vaccine","companyName":"Seqirus","companyId":"seqirus","modality":"Biologic","firstApprovalDate":"","aiSummary":"This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}